Literature DB >> 10021954

Comparison of epidural anaesthesia with ropivacaine 0.5% and bupivacaine 0.5% for caesarean section.

E Crosby1, A Sandler, B Finucane, D Writer, D Reid, J McKenna, M Friedlander, A Miller, S O'Callaghan-Enright, H Muir, R Shukla.   

Abstract

PURPOSE: To compare ropivacaine 0.5% with bupivacaine 0.5% for epidural anaesthesia for Caesarean section.
METHODS: Healthy pregnant women, scheduled for elective Caesarean section were enrolled into this randomized, double-blind, parallel-group study. Epidural block was obtained with 20-30 ml of ropivacaine (group R) or bupivacaine (group B) and surgery started when anaesthesia was reached T6. Maternal heart rate and blood pressure and fetal heart rate were assessed before the test dose and at five minute intervals until the end of surgery. At the same intervals, sensory and motor block characteristics were determined. Apgar scores and Neurologic and Adaptive Capacity Scores (NACS) were determined after delivery. Adverse events were recorded.
RESULTS: Sixty-five patients were enrolled and data from 61 were available for analysis; 30 ropivacaine and 31 bupivacaine. Time from the end of the last injection to the start of surgery was 46 +/- 13 min (mean +/- SD) in gp R and 53 +/- 25 min in gp B (P:NS). The median duration of analgesia varied between 1.7 and 4.2 hr in gp R and between 1.8 and 4.4 hr in gp B (P:NS). In patients who developed Bromage 4 block, it persisted longer in those in gp B (2.5 hr) than in gp R (0.9 hr) (P < 0.05). The quality of analgesia was satisfactory in 27/29 patients (93%) in gp R and 27/31 patients (87%) in gp B (P:NS), although supplemental i.v. opioid was required in ten and seven patients, respectively. The most common adverse events in the mother were hypotension (63% gp R and 61% in gp B) (NS) and nausea (30% and 58%, in group R and B, respectively) (P = 0.05). Apgar scores were 7 after five minutes in all neonates.
CONCLUSION: Ropivacaine 0.5% and bupivacaine 0.5% provided effective epidural anaesthesia for Caesarean section although supplementation with i.v. opioid was commonly required.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10021954     DOI: 10.1007/BF03012393

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  12 in total

Review 1.  Ropivacaine: a review of its use in regional anaesthesia and acute pain management.

Authors:  Dene Simpson; Monique P Curran; Vicki Oldfield; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Ropivacaine: an update of its use in regional anaesthesia.

Authors:  K J McClellan; D Faulds
Journal:  Drugs       Date:  2000-11       Impact factor: 9.546

Review 3.  Benefit-risk assessment of ropivacaine in the management of postoperative pain.

Authors:  Wolfgang Zink; Bernhard M Graf
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

4.  Progress in analgesia for labor: focus on neuraxial blocks.

Authors:  J Sudharma Ranasinghe; David J Birnbach
Journal:  Int J Womens Health       Date:  2010-08-09

5.  No Difference in Early Analgesia Between Liposomal Bupivacaine Injection and Intrathecal Morphine After TKA.

Authors:  John W Barrington; Roger H Emerson; Scott T Lovald; Adolph V Lombardi; Keith R Berend
Journal:  Clin Orthop Relat Res       Date:  2017-01       Impact factor: 4.176

6.  Epidural anesthesia and post-operative analgesia for bilateral inguinal mesh hernioplasty: Comparison of equipotent doses of ropivacaine and bupivacaine.

Authors:  Sara Korula; Grace Maria George; Shaloo Ipe; Saramma P Abraham
Journal:  Saudi J Anaesth       Date:  2011-07

7.  Ropivacaine: A review of its pharmacology and clinical use.

Authors:  Gaurav Kuthiala; Geeta Chaudhary
Journal:  Indian J Anaesth       Date:  2011-03

8.  Continuous ropivacaine infusion vs transdermal fentanyl for providing postoperative analgesia following temporomandibular joint interpositional gap arthroplasty.

Authors:  Satish Dhasmana; Vibha Singh; U S Pal
Journal:  Natl J Maxillofac Surg       Date:  2010-07

9.  Epidural sustained release ropivacaine prolongs anti-allodynia and anti-hyperalgesia in developing and established neuropathic pain.

Authors:  Teng-Fei Li; Hui Fan; Yong-Xiang Wang
Journal:  PLoS One       Date:  2015-01-24       Impact factor: 3.240

Review 10.  Update on the clinical utility and practical use of ropivacaine in Chinese patients.

Authors:  Man Li; Li Wan; Wei Mei; Yuke Tian
Journal:  Drug Des Devel Ther       Date:  2014-09-09       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.